deltatrials
Recruiting PHASE1 INTERVENTIONAL 9-arm NCT04137900

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

Sponsor: CTI Clinical Trial and Consulting Services

Conditions Advanced Unresectable Solid Tumor Metastatic Solid Tumor
Interventions TAB004 Toripalimab
Updated 17 times since 2019 Last updated: Feb 1, 2024 Started: Oct 30, 2019 Primary completion: Mar 31, 2026 Completion: Mar 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Unresectable Solid Tumor and Metastatic Solid Tumor and is currently actively recruiting participants. CTI Clinical Trial and Consulting Services leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Dec 2020 · 5 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Mar 2023 · 8 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jun 2023 — Mar 2024 [monthly]

    Recruiting PHASE1

▶ Show 12 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  2. Jul 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  4. Jan 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  5. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  6. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  9. Jul 2020 — Dec 2020 [monthly]

    Recruiting PHASE1

  10. Mar 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  11. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  12. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

    First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CTI Clinical Trial and Consulting Services
  • Shanghai Junshi Bioscience Co., Ltd.
  • TopAlliance Biosciences
Data source: TopAlliance Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Birmingham, United States , Boca Raton, United States , Boston, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Detroit, United States , Houston, United States and 13 more locations